Date:7/29/2011

e statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about The Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .

'/>"/>

SOURCE The Female Health Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
2. The Female Health Companys Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms
3. The Female Health Company Declares 2nd Quarter Dividend of $0.05/share
4. The Me-Covery: Saatchi & Saatchi Wellness and Time Inc.s Health Brand Reveal Historic Shift in Female Consumer Behavior
5. Co-Promotion of a New Medical Device for Female Infertility Announced
6. The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup
7. Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predecessor
8. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
9. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
10. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
11. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females